(NASDAQ:CAPR) announced today that it intends to file a Biologics License Application [BLA] for deramiocel for the treatment of patients with Duchenne Muscular Dystrophy [DMD] cardiomyopathy.

A systematic analysis evaluates the incidence of germline mosaicism in Duchenne muscular dystrophy (DMD), as well as recurrence risks. Evaluation of germline mutations is not the current standard of ...

Capricor Therapeutics will soon begin filing an application seeking U.S. approval of its cell therapy deramiocel for cardiomyopathy, a disease of the heart’s muscle, in people with Duchenne muscular ...

"My medicine is making me stronger," 7-year-old Hudson Sanford says after receiving a breakthrough gene therapy for Duchenne ...

The importance of family and community support took on a new meaning when our son Michael was diagnosed with Duchenne muscular dystrophy (DMD), a rare and severe neuromuscular disease. We started ...

We hypothesize that Duchenne muscular dystrophy and autism spectrum disorder/pervasive developmental disorder co-occur with a greater than random frequency. In this study, we set out to reject the ...

Under the direction of Bo Hoon Lee, MD, from… Researchers have discovered a new, unrecognized type of muscular dystrophy that’s caused by inherited mutations in the SNUPN gene, a study reports. Most ...

Muscular dystrophy is most commonly diagnosed by examining ... of ventricular function can occur in the presence or absence of symptoms of congestive heart failure. Cardiac rhythm disturbances ...

Wave Life Sciences has met its goal in a Duchenne muscular dystrophy (DMD) study, positioning it to talk to regulators about accelerated approval while continuing to track patients through to the ...

“Duchenne muscular dystrophy (DMD) is one of the most severe ... rather than just managing its symptoms. There was just one problem. At the time, Elevidys was only eligible for children up ...